A combination of the medicines eltrombopag and cyclosporine A may be effective for controlling immune thrombocytopenia (ITP) that doesn’t respond well to initial treatment…
News
Scientists have developed a gene-editing therapy to selectively disable the genetic mutations responsible for Von Willebrand disease (VWD) type 2, regardless of subtype, potentially…
The shape of the ADAMTS13 enzyme during remission (a period when symptoms ease or disappear) may help predict which people with immune-mediated thrombotic thrombocytopenic…
Lipid, or fat, metabolism is altered in people with immune thrombocytopenia (ITP), resulting in distinct metabolic signatures that could help distinguish ITP patients from healthy…
A recent case report highlights the challenges of performing surgery in a patient with more than one bleeding disorder. Two doctors in Portugal described their…
More than half of individuals who recover from an acute episode of immune-mediated thrombotic thrombocytopenic purpura (iTTP) may have silent brain damage — where…
The size of platelets, the cell fragments that help blood clot, and the levels of certain immune cells in the body may help predict the…
Bleeding Disorders News brought you daily coverage of the latest clinical research and scientific breakthroughs related to bleeding disorders in 2025. Here are the…
The approved immune thrombocytopenia (ITP) treatment Doptelet (avatrombopag) may be able to be repurposed to treat certain bone diseases, according to a new…
People with von Willebrand disease (VWD) or hemophilia A are more likely to experience serious bleeding in the first month after a kidney transplant, a…
